曲妥珠单抗联合放化疗治疗HER-2阳性晚期乳腺癌的临床疗效以及疾病预后分析  

Clinical Efficacy and Prognosis Analysis of Trastuzumab Combined with Chemoradiotherapy in the Treatment of HER-2 Positive Advanced Breast Cancer

作　　者：谭明 向东华 TAN Ming;XIANG Donghua.(Hubei Enshi Center Hospital of Integrated Traditional Chinese and Western Medicine,Enshi,44500)

机构地区：[1]湖北恩施土家族苗族自治州中心医院,445000

出　　处：《实用癌症杂志》2018年第10期1714-1716,共3页The Practical Journal of Cancer

摘　　要：目的探讨曲妥珠单抗辅助治疗HER-2阳性晚期乳腺癌的疗效。方法选取60例HER-2阳性晚期乳腺癌患者,随机分为观察组和对照组,每组30例。对照组采用单纯放化疗治疗,观察组采用曲妥珠单抗联合放化疗治疗。比较2组患者的肿瘤治疗效果、预后情况以及毒副作用。结果观察组患者的总有效率和疾病控制率均显著高于对照组(P <0. 05);观察组患者的无进展生存期(PFS)、总生存期(OS)以及生活质量评分(QOL)优于对照组(P <0. 05);观察组治疗期间因化疗药物带来的毒副作用明显低于对照组(P <0. 05)。结论曲妥珠单抗联合放化疗治疗HER-2阳性晚期乳腺癌的疗效较好,对于杀灭肿瘤细胞有积极作用,同时可延长患者生存时间,在一定程度上可改善预后。Objective To investigate the efficacy of trastuzumab in adjuvant treatment of HER-2 positive advanced breast cancer. Methods 60 cases of HER-2 positive advanced breast cancer were enrolled in this study,and they were randomly divided into the observation group （30 cases） and the control group （30 cases）.The Control group was treated with chemoradiotherapy.The Observation group was treated with trastuzumab combined with chemoradiotherapy.The clinical efficacy,survival and toxicity of the 2 groups were compared. Results The total effective rate and the disease control rate in the observation group were higher than the control group （ P〈0.05）.Progression free survival（FPS）,overall survival（OS）and Quality of life（QOL）in the observation group were higher than the control group （ P〈0.05）.The rate of adverse reactions in the observation group was lower than the control group （ P〈0.05）. Conclusion The clinical efficacy of trastuzumab combined with chemoradiotherapy in the treatment of HER-2 positive advanced breast cancer is good,which plays a positive role in killing tumor cells,prolongs the survival time of patients,and improves the prognosis to a certain extent.

关 键 词：曲妥珠单抗 乳腺癌 放化疗 HER-2阳性 预后 

分 类 号：R737.9[医药卫生—肿瘤]